auristatin e

Auristatin E, a cytotoxic tubulin modifier, disrupts cell division by inhibiting tubulin polymerisation. This compound demonstrates potent and selective antitumor activities, serving as an MMAE analog and cytotoxin in antibody-drug conjugates.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

Aminobenzenesulfonic auristatin E is a potent antitumor agent-linker conjugate for Antibody-Drug Conjugates (ADC). It utilizes Auristatin E (a cytotoxic tubulin modifier) connected through the ADC linker, Aminobenzenesulfonic [1], to exhibit significant antitumor activity.

Aminobenzenesulfonic Auristatin E TFA, an agent-linker conjugate for ADC, exhibits potent antitumor activity. It employs Auristatin E (a cytotoxic tubulin modifier) connected through the ADC linker Aminobenzenesulfonic [1].

Aminobenzenesulfonic auristatin E-D8 is a deuterated version of Aminobenzenesulfonic auristatin E (T74483), which forms part of an antibody-drug conjugate. This compound is synthesized by linking the cytotoxic microtubule modifier Auristatin E with the ADC linker Aminobenzenesulfonic, endowing it with antitumor activity.

(4R,5S)-MonomethylauristatinE intermediate-6 is an intermediate reactant in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity and is widely utilized as the cytotoxic component in antibody-drug conjugates (ADC Cytotoxin).

MonomethylauristatinE intermediate-8 is an intermediate compound in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) acts as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

MonomethylauristatinE intermediate-10 is an intermediate used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs) [ADC Cytotoxin].

MonomethylauristatinE intermediate-17 is an intermediate compound used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) functions as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

AuristatinE-d8 is the deuterated form of AuristatinE. AuristatinE is a cytotoxic microtubule polymerization inhibitor with selective anti-tumor activity. It serves as the cytotoxin in antibody-drug conjugates (ADC). By blocking microtubule polymerization, AuristatinE inhibits cell division and holds potential for research in B-cell malignancies. It is a synthetic analog of Dolastatin 10, composed of a linear peptide with four amino acids.

Monomethyl auristatin E (MMAE) (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) and a HER2-targeted cytotoxic agent, consisting of an anti-HER2 monoclonal antibody conjugated to MMAE via a cleavable linker, used for the treatment of HER2-expressing solid tumors including gastric cancer, breast cancer, and urothelial carcinoma.

MMAE-D8 is a deuterated compound of MMAE (T6897-GMP) (Monomethyl Auristatin), suitable for isotope tracing. MMAE (T6897-GMP) is a tubulin microtubule inhibitor that suppresses cancer cell mitosis and is frequently employed in antibody-drug conjugate (ADC) development.

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

MMAU (β-D-Glucuronylmonomethylauristatin E) is a payload that is relatively stable in its unbound free state. Lysosomal enzymes convert it to a deglycosylated state, which activates the cytotoxicity of the payload.

lifastuzumAb is a humanized IgG1-like monoclonal antibody against NaPi2b, often coupled with the anti-mitotic agent monomethyl auristatin E, which inhibits cell division by blocking the polymerization of microtubule proteins.

Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) specifically targeting the receptor tyrosine kinase AXL. it consists of a monoclonal antibody linked to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) and demonstrates significant inhibitory potential against high AXL-expressing non-small cell lung cancer (NSCLC), including tumors with resistance to EGFR inhibitors like Osimertinib.

m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) for Trastuzumab, positioned distally from the monomethyl auristatin E (MMAE) payload to produce an ADC with modified hydrophilicity, antigen binding, and in vitro potency[1].

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a potent tubulin inhibitor and toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2, serving as the cytotoxic component in this formulation.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, is conjugated via a DBCO-(PEG)3-vc-PAB linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker composed of the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the SuO-Val-Cit-PAB peptide.